Data Breach

ExecuPharm Data Breach Investigation

Posted on

Migliaccio & Rathod is currently investigating pharmaceutical firm ExecuPharm for failure to adequately safeguard employees’ private information, resulting in a data breach. On March 13th, an unknown third party deployed ransomware to ExecuPharm’s IT systems, seeking to extract payment in return for an encryption key. As part of the cyberattack, ExecuPharm employees were sent phishing […]

Product Defect

Metformin Carcinogenic Contaminants Investigation

Posted on

Migliaccio & Rathod LLP is currently investigating manufacturers of the widely used diabetes drug metformin, known by the common brand names Glucofage, Riomet, and Glumetza, for product contamination. Online pharmacy Valisure tested various metformin batches for impurities containing N-nitrosodimethylamine, or NDMA, a probable human carcinogen, and found sixteen contaminated batches. One batch contained sixteen times […]

Product Defect

Migliaccio & Rathod LLP Appointed to Help Lead Valsartan Litigation

Posted on

Migliaccio & Rathod LLP File Nationwide Class Action Complaint Against Major Pharmaceutical Companies for Contaminated Valsartan Sales and Are Appointed by Court to Plaintiffs’ Steering Committee Migliaccio & Rathod, as an appointed member of the Plaintiffs’ Steering Committee and co-lead of the Medical Monitoring group, have filed a Consolidated Amended Class Action Complaint against Teva, […]

Product Defect

Valsartan Carcinogenic Contaminants Investigation

Posted on

Migliaccio & Rathod LLP has filed a class action lawsuit against certain manufacturers of Valsartan, an angiotensin II receptor blocker used to treat high blood pressure and heart failure. The Food and Drug Administration issued a recall of Valsartan because it contained significant levels of N-nitrosodimethylamine (NDMA)—a probable human carcinogen—the long-term exposure of which increases […]